1). Similar to prostatic carcinoma tissue, positive staining for PD1/PDL1 was also detected in the cytoplasm of the epithelial cells and lymphocytes in benign tissues (Fig. 2). Fig. 1 Representative immunohistochemical (IHC) staining of PD1 and PDL1 in prostate cancer tissues. A, C ...
Elusive biomarkers of sensitivity to combined PD1/CTLA4 blockade in metastatic castration-resistant prostate cancerdoi:10.1016/j.annonc.2024.10.001E.S. AntonarakisElsevier LtdAnnals of Oncology
Besides, Submap mapping was used to investigate the response of anti-CTLA4/PD1 immunotherapy. Considering the distinction in chemotherapeutic sensitivity in prostate cancer patients, the IC50 values of 138 antitumor drugs in Genomics of Drug Sensitivity in Cancer (GDSC, https://www.cancerrxgene.org/...
RIPR-PD-1 promoted the effect of checkpoint blockade and improved the therapeutic efficacy of anti-PD1 antibodies.58 In the following paragraphs, we summarize how key molecules and multiple pathways as well as noncoding RNAs regulate the expression of PD-L1 in prostate cancer cells (Figure 1; ...
Radiotherapy in combination with androgen deprivation therapy (ADT) is a standard treatment option for men with localized and locally advanced prostate cancer. However, emerging clinical evidence suggests that radiotherapy can be incorporated into multimodality therapy regimens beyond ADT, in combinations tha...
Only the presence of insufficient mismatch repair has been recognized by the clinical guidelines as a transversal agnostic for anti-PD1 therapy [203]. The synergistic effect of anti-D-1/PD-L1 and anti-CTLA-4 has been reported in renal cancer and melanoma [204, 205]. It has been shown ...
Prostate adenocarcinoma (PRAD) persists as the predominant non-cutaneous malignancy diagnosed in males, which is a primary contributor to cancer-related mortality globally. It is reported that the progression of prostate adenocarcinoma is associated with
For instance, the lack of response to an anti-PD-L1 agent in malignant tumors revealed that stromal TGF-β dampens PD-1/PD-L1 blockade.20 The present study revealed that prostate cancer (PCa) cell-derived exosomes transport IL-8 into CD8+ T cells and hamper CD8+ T cell proliferation by...
Last year, Lu et al [175], demonstrated that robust synergistic responses could be achieved in mCPRC mouse models when immune checkpoint blockade (anti-CTLA4 and anti-PD1) was combined with MDSC-targeted therapy (cabozantinib and BEZ235), while the single use of either one of them engendered ...
19. The method of claim 17, wherein the castration resistant prostate cancer (CrPC) comprises small cell cancer, large cell cancer, neuroendocrine prostate cancer (NEPC), castration resistant prostate cancer neuroendocrine (CrPC-NE) and castration resistant prostate cancer (CrPC) pre-treated with ...